TAK - Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)
2025-08-15 12:24:05 ET
Investment Overview
When I last covered Intellia Therapeutics, Inc. ( NTLA ) for Seeking Alpha at the end of May, the share price of the Cambridge, Massachusetts-based pharma company, developing gene therapies using CRISPR technology, was tanking. This was after it reported that a patient with ATTR-CM (transthyretin amyloid cardiomyopathy) being treated with its candidate nexiguran ziclumeran ("nex-z"), had experienced grade 4 liver transaminase elevations....
Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)